Abstract
Background Approximately half of patients discharged following COVID-19 related hospitalisation are reported to suffer from persisting respiratory symptoms. We assess the prevalence of long term radiological and functional pulmonary sequelae in survivors from COVID-19 and other viral pneumonia in published literature.
Methods We performed systematic review and meta-analysis of all original studies in adults admitted to hospital with SARS-CoV-2, SARS-CoV, MERS-CoV, or Influenza pneumonia and followed within 12 months from discharge. Searches were run on MEDLINE and Embase, with the last update on 1st March 2021. Primary outcomes were presence of 1) radiologic sequelae at CT scans; 2) restrictive impairment; 3) reduced diffusing capacity for carbon monoxide (DLCO). This review is registered on PROSPERO, CRD42020183139.
Results Sixty studies were included for qualitative synthesis, of which 41 were suitable for meta-analysis. On follow up CT scans, the overall estimated proportion was 0·56 (95%CI 0·44 to 0·66, I2= 94·44%) for inflammatory changes, and 0·40 (95%CI 0·29 to 0·52, I2=95·19%) for fibrotic findings. In SARS-CoV-2 specifically, proportions were estimated at 0·43 (95%CI 0·32 to 0·56, I2=94.60%) and 0·30 (95%CI 0·19 to 0·43, I2=94.89%) for inflammatory and fibrotic findings, respectively. Overall proportion for restrictive impairment was 0·19 (95%CI 0·12 to 0·27, I2=94·46%), DLCO reduction was estimated at 0·45 (95%CI 0·38 to 0·52, I2=90·10). Elevated radiological and functional estimates persisted across follow-up times. Confidence in the estimates was deemed very low as studies were largely observational without control groups, heterogeneity in estimates was high but was not clearly attributable to between-study differences of severity or design.
Conclusion Although estimates of prevalence are likely limited by differences in case mix and initial severity, a substantial proportion of radiological and functional sequelae are observed following viral pneumonitis, including COVID-19. This highlights the importance of vigilant radiological and functional follow up.
Funding National Institute for Health Research (NIHR)
Competing Interest Statement
LF, SM, FK, WC, JX, KR, AS, GJ and IS all report no competing interests with respects to the study. GJ reports fees/funding from Biogen, Galapagos, Galecto, GlaxoSmithKline, Heptares, Medimmune, PharmAkea, BristolMyersSquib, Chiesi, Boehringer Ingelheim, Pliant, Roche, RedX, NuMedii, NordicBiosciences, Veracyte.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=183139
Funding Statement
Funding was supported by National Institute for Health Research (NIHR), the funders had no involvement in any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Nottingham Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
PROSPERO registration number: CRD42020183139
Data Availability
Data are publicly available in published manuscript, and can be shared upon reasonable request
